Patents by Inventor Robert RENNIE
Robert RENNIE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240132528Abstract: The present patent application discloses the compounds according to Formula I shown below, or pharmaceutically acceptable salts thereof, wherein JB, n, R1, R2, R3, R4, R5, m and X as defined herein.Type: ApplicationFiled: August 31, 2023Publication date: April 25, 2024Inventors: James Edward Sheppeck, Paul Allan Renhowe, Ara Mermerian, Timothy Claude Barden, Glen Robert Rennie, Rajesh R. Iyengar, Takashi Nakai
-
Patent number: 11897887Abstract: The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutically acceptable salts, pharmaceutical formulations comprising them as well as their phosphate ester prodrugs, and their uses alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) and/or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP), or both, or the upregulation of the NO pathway is desirable. The compounds are of Formula I.Type: GrantFiled: December 19, 2018Date of Patent: February 13, 2024Assignee: Tisento Therapeutics Inc.Inventors: Glen Robert Rennie, Paul Allan Renhowe, Takashi Nakai, Ara Mermerian, Helen Cumberbatch
-
Patent number: 11731977Abstract: The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP), or both, or an upregulation of the NO pathway is desirable.Type: GrantFiled: September 27, 2021Date of Patent: August 22, 2023Assignee: Cyclerion Therapeutics, Inc.Inventors: Glen Robert Rennie, Rajesh R. Iyengar, Thomas Wai-Ho Lee, Paul Allan Renhowe, Joon Jung, Kim Tang
-
Publication number: 20230115350Abstract: The present disclosure provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.Type: ApplicationFiled: July 29, 2022Publication date: April 13, 2023Inventors: Glen Robert Rennie, C. Eric Schwartz, Louise Kirman, Dale Porter, Ling Song
-
Publication number: 20230106002Abstract: Compounds of Formulae I? and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.Type: ApplicationFiled: December 20, 2021Publication date: April 6, 2023Inventors: Takashi Nakai, Joel Moore, Nicholas Robert Perl, Rajesh R. Iyengar, Ara Mermerian, G-Yoon Jamie Im, Thomas Wai-Ho Lee, Colleen Hudson, Glen Robert Rennie, Lei Jia, Paul Allan Renhowe, Timothy Claude Barden, Xiang Y. Yu, James Edward Sheppeck, Karthik Iyer, Joon Jung, George Todd Milne, Kimberly Kafadar Long, Mark G. Currie
-
Publication number: 20230098872Abstract: The present disclosure provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.Type: ApplicationFiled: March 25, 2022Publication date: March 30, 2023Inventors: Glen Robert Rennie, C. Eric Schwartz, Louise Kirman, Dale Porter, Ling Song
-
Publication number: 20230053649Abstract: The present disclosure provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.Type: ApplicationFiled: June 24, 2022Publication date: February 23, 2023Inventors: Glen Robert Rennie, C. Eric Schwartz, Dale Porter, Ling Song
-
Publication number: 20220017515Abstract: The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) and/or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP) might be desirable.Type: ApplicationFiled: September 27, 2021Publication date: January 20, 2022Inventors: Glen Robert Rennie, Timothy Claude Barden, Thomas Wai-Ho Lee, Rajesh R. Iyengar, Takashi Nakai, Ara Mermerian, Lei Jia, Karthik Iyer, G-Yoon Jamie Im, Paul Allan Renhowe, Joon Jung, Peter Germano, Kim Tang
-
Publication number: 20220009937Abstract: The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP), or both, or an upregulation of the NO pathway is desirable.Type: ApplicationFiled: September 27, 2021Publication date: January 13, 2022Inventors: Glen Robert Rennie, Rajesh R. Iyengar, Thomas Wai-Ho Lee, Paul Allan Renhowe, Joon Jung, Kim Tang
-
Patent number: 11207323Abstract: Compounds of Formulae I? and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.Type: GrantFiled: March 13, 2020Date of Patent: December 28, 2021Assignee: Cyclerion Therapeutics, Inc.Inventors: Takashi Nakai, Joel Moore, Nicholas Robert Perl, Rajesh R. Iyengar, Ara Mermerian, G-Yoon Jamie Im, Thomas Wai-Ho Lee, Colleen Hudson, Glen Robert Rennie, Lei Jia, Paul Allan Renhowe, Timothy Claude Barden, Xiang Y. Yu, James Edward Sheppeck, Karthik Iyer, Joon Jung, George Todd Milne, Kimberly Kafadar Long, Mark G. Currie
-
Patent number: 11180493Abstract: The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) and/or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP) might be desirable. Various compounds are disclosed, including those of Formula (I).Type: GrantFiled: November 7, 2017Date of Patent: November 23, 2021Assignee: Cyclerion Therapeutics, Inc.Inventors: Glen Robert Rennie, Timothy Claude Barden, Thomas Wai-Ho Lee, Rajesh R. Iyengar, Takashi Nakai, Ara Mermerian, Lei Jia, Karthik Iyer, G-Yoon Jamie Im, Paul Allan Renhowe, Joon Jung, Peter Germano, Kim Tang
-
Publication number: 20210221793Abstract: Compounds are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.Type: ApplicationFiled: January 7, 2021Publication date: July 22, 2021Inventors: Timothy Claude Barden, James Edward Sheppeck, Glen Robert Rennie, Paul Allan Renhowe, Nicholas Robert Perl, Takashi Nakai, Ara Mermerian, Thomas Wai-Ho Lee, Joon Jung, Lei Jia, Karthik Iyer, Rajesh R. Iyengar, G-Yoon Jamie Im
-
Publication number: 20210214364Abstract: The present patent application discloses at least the compounds according to Formula l shown below, or pharmaceutically acceptable salts thereof, wherein ringjB,n, JD, J,0, X, X1, J, RC, and W are as defined herein. These compounds are useful as simulators of soluble sGC.Type: ApplicationFiled: December 15, 2020Publication date: July 15, 2021Inventors: Paul Allan Renhowe, James Edward Sheppeck, Takashi Nakai, Karthik Iyer, Nicholas Robert Perl, Glen Robert Rennie, Mark G. Currie, Kimberly Kafadar Long, George Todd Milne, Rajesh R. Iyengar
-
Publication number: 20210087198Abstract: The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP), or both, or an upregulation of the NO pathway is desirable.Type: ApplicationFiled: December 4, 2020Publication date: March 25, 2021Inventors: Glen Robert Rennie, Rajesh R. Iyengar, Thomas Wai-Ho Lee, Paul Allan Renhowe, Joon Jung, Kim Tang
-
Patent number: 10927136Abstract: The present patent application discloses the compounds according to Formula (I) shown below, or pharmaceutically acceptable salts thereof wherein JB, n, R1, R2, R3, R4, R5, m and X as defined herein.Type: GrantFiled: July 6, 2017Date of Patent: February 23, 2021Assignee: Cyclerion Therapeutics, Inc.Inventors: James Edward Sheppeck, Paul Allan Renhowe, Ara Mermerian, Timothy Claude Barden, Glen Robert Rennie, Rajesh R. Iyengar, Takashi Nakai
-
Patent number: 10858363Abstract: The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP), or both, or an upregulation of the NO pathway is desirable.Type: GrantFiled: February 12, 2019Date of Patent: December 8, 2020Assignee: Cyclerion Therapeutics, Inc.Inventors: Glen Robert Rennie, Rajesh R. Iyengar, Thomas Wai-Ho Lee, Takashi Nakai, Ara Mermerian, Lei Jia, G-Yoon Jamie Im, Paul Allan Renhowe, Joon Jung, Peter Germano, Karthik Iyer, Timothy Claude Barden, Kim Tang
-
Publication number: 20200377508Abstract: The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutically acceptable salts, pharmaceutical formulations comprising them as well as their phosphate ester prodrugs, and their uses alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) and/or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP), or both, or the upregulation of the NO pathway is desirable. The compounds are of Formula I.Type: ApplicationFiled: December 19, 2018Publication date: December 3, 2020Inventors: Glen Robert Rennie, Paul Allan Renhowe, Takashi Nakai, Ara Mermerian, Helen Cumberbatch
-
Patent number: 10844064Abstract: The present patent application discloses at least the compounds according to Formula I? shown below, or pharmaceutically acceptable salts thereof, wherein ring D, ring A, ring E, JB, n, JD, J, X, Z, Z1, RC1, RC2, Y, R9, o and W are as defined herein.Type: GrantFiled: September 16, 2015Date of Patent: November 24, 2020Assignee: Cyclerion Therapeutics, Inc.Inventors: Glen Robert Rennie, Nicholas Perl, Ara Mermerian, Joon Jung, Lei Jia, Rajesh R. Iyengar, G-Yoon Jamie Im, Timothy Claude Barden, James Edward Sheppeck, Paul Allan Renhowe, Takashi Nakai, Thomas Wai-Ho Lee, Karthik Iyer
-
Publication number: 20200316065Abstract: Compounds of Formulae I? and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.Type: ApplicationFiled: March 13, 2020Publication date: October 8, 2020Inventors: Takashi Nakai, Joel Moore, Nicholas Robert Perl, Rajesh R. Iyengar, Ara Mermerian, G-Yoon Jamie Im, Thomas Wai-Ho Lee, Colleen Hudson, Glen Robert Rennie, Lei Jia, Paul Allan Renhowe, Timothy Claude Barden, Xiang Y. Yu, James Edward Sheppeck, Karthik Iyer, Joon Jung, George Todd Milne, Kimberly Kafadar Long, Mark G. Currie
-
Patent number: 10689269Abstract: There is described a novel fluid treatment device that can induce Dean Vortices in the flowing fluid, and then induce a new set of Dean Vortices at an angle to those in the first set. Each subsequent curved section can induce vortices at an angle to those in the last curved section. This reactor has the effect of repeatedly twisting and splitting the fluid flow, resulting in targeted mixing similar to that of static mixers without the necessity of utilizing physical mixers. This is also an improvement over helical tubing configurations that generate only a single set of vortices and do not split and mix the flow.Type: GrantFiled: December 12, 2016Date of Patent: June 23, 2020Assignee: TROJAN TECHNOLOGIESInventors: Mark Adrian Kustermans, Michael Sasges, Robert Rennie